| Idiopathic nonspecific interstitial pneumonia (iNSIP) |
|
Yong Suk Jo1, Hyun-Kyung Lee2, Sun Hyo Park3, Joon Sung Joh4, Hye Jin Jang5, Jong Sun Park6, on behalf of Korean Interstitial Lung Disease Study Group |
1Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Republic of Korea
3Division of Pulmonology, Respiratory Center, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Republic of Korea
4Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Center, Seoul, Republic of Korea
5Division of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea
6Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea |
Correspondence:
Jong Sun Park,
Email: jspark.im@gmail.com
|
|
Received: 4 November 2024 • Revised: 22 December 2024 • Accepted: 30 December 2024 |
| Abstract |
|
Idiopathic nonspecific interstitial pneumonia (iNSIP) is recognized as a distinct entity among various types of idiopathic interstitial pneumonias (IIP). It is identified histologically by the nonspecific interstitial pneumonia (NSIP) pattern. A diagnosis of iNSIP is feasible once secondary causes or underlying diseases are ruled out. Usually presenting with respiratory symptoms such as shortness of breath and cough, iNSIP has a subacute or chronic course. It predominantly affects females aged 50 to 60 years who are non-smokers. Key imaging findings on chest high-resolution computed tomography (HRCT) include bilateral reticular opacities in lower lungs, traction bronchiectasis, reduced lung volumes and, ground-glass opacities. Abnormalities are typically diffuse across both lungs with subpleural distributions. Treatment often involves systemic steroids, either alone or in combination with other immunosuppressants, although evidence supporting effectiveness of these treatments is limited. Prognosis is generally more favorable for iNSIP than for idiopathic pulmonary fibrosis (IPF), with many studies reporting a 5-year survival rate above 70%. Antifibrotic agents should be considered in a condition, , termed progressive pulmonary fibrosis (PPF), where pulmonary fibrosis progressively worsens. |
| Key Words:
Interstitial Lung Disease, idiopathic nonspecific interstitial pneumonia |
|
PDF Links
Full text via DOI
Download Citation
